Magnetic Resonance Imaging Development for High Resolution Atrial Structural and Functional Characterization

This Magnetic Resonance imaging study of the heart aims to acquire images and measures of:

• Left atrial cine: compressed sensing cine imaging strategies will be tested for LA assessment by optimizing spatial and temporal resolution providing the best image quality relative to acceptable acquisition times. The whole heart should be covered during acquisition. Image quality and diagnosis of LA contraction preservation will be performed.
• Myocardial tissue characterization including:

• 3D isotropic ECG-gated with respiratory navigation late gadolinium enhancement (LGE) sequence for high resolution imaging of myocardial injury and fibrosis.
• High resolution free-breathing T1/T2 mapping to quantify myocardial water content and measure native T1 relaxation and extracellular volume. 2D free breathing LGE will complement the protocol.
• Cardiac adipose tissue imaging will be performed using gated Dixon imaging. Pericardial adipose tissue (PAT) will be measured covering the whole heart including groove epicardial adipose tissue (EAT).
• Flow measurements: test and optimize a 4D flow approach for the heart and aorta using compressed sensing and multi velocity encoding (VENC) encoding to insure high and precise multi-chamber velocity imaging(100, 150, 200, 250 cm/s). Two-chamber (including left appendage) in plane velocities will be compared between high resolution 2D and 4D. Of, note, such multi-VENC approach is mandatory for LA imaging because of the large heterogeneity of blood flow velocities within the LA during the cardiac cycle.
• Technology validation: comparison of cardiac triggering using the beat sensor vs. surface ECG-gating will be tested as a means of improving patient experience and speed up MRI acquisition for subsequent population imaging.

This task will be performed at the Cardiovascular MRI Imaging Platform and Core Lab at the Pitié-Salpêtrière Hospital site by SU-ICAN & APHP (ICT), SU-LIB and SIEMENS partners with the goal to optimize, test and validate innovative approaches before wider application.

Inclusion criteria

For all groups of AF patients:

• Over 18 years of age
• Participation to the MAESTRIA-AFNET 10 study
• Able to undergo an injected MRI examination
• Able to give consent
• Affiliated to French social security system

Specific inclusion criteria of AF patients (same as MAESTRIA-AFNET 10) Group 1: patients with paroxysmal AF (no AF during exam) clinically defined as AF episodes less than one week Group 2: patients with persistent AF, clinically defined as AF episodes longer than one week Group 3: patients with permanent AF, with no documented sinus rhythm or possibility to restore sinus rhythm by any means

For healthy volunteers (Group 4):

• Over 18 years of age (including 30 subjects < 60 years)
• Able to undergo an MRI examination
• Able to give consent
• Affiliated to French social security system

Exclusion criteria

For all groups

• Deprived of liberty or under legal protection (under guardianship or curatorship)
• Kidney disease with GFR <30 mL / min (because of the risks linked to the injection of DOTAREM ™ and iodine)
• Pregnant woman, breastfeeding, of childbearing age in the absence of effective contraception
• MRI contraindication (claustrophobia, patients with metallic foreign bodies)
• Participation to another interventional clinical trial (Jardé 1) For patients
• Patients with a history of renal disease (renal transplant, single kidney, renal cancer)
• Patients who have received a dose of contrast in the last 24 hours
• Patients who had a previous allergic or anaphylactic reaction to gadolinium For volunteers
• Subjects with known cardiovascular pathology or under cardiovascular treatment
• Subjects with cardiovascular history
• Subjects with cardiac rhythm or conduction disorders